1
|
Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021; 13:cancers13153766. [PMID: 34359666 PMCID: PMC8345167 DOI: 10.3390/cancers13153766] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 07/21/2021] [Accepted: 07/24/2021] [Indexed: 12/12/2022] Open
Abstract
Neuroendocrine carcinomas (NEC) are rare tumors with a rising incidence. They show poorly differentiated morphology with a high proliferation rate (Ki-67 index). They frequently arise in the lung (small and large-cell lung cancer) but rarely from the gastrointestinal tract. Due to their rarity, very little is known about digestive NEC and few studies have been conducted. Therefore, most of therapeutic recommendations are issued from work on small-cell lung cancers (SCLC). Recent improvement in pathology and imaging has allowed for better detection and classification of high-grade NEN. The 2019 World Health Organization (WHO) classification has described a new entity of well-differentiated grade 3 neuroendocrine tumors (NET G-3), with better prognosis, that should be managed separately from NEC. NEC are aggressive neoplasms often diagnosed at a metastatic state. In the localized setting, surgery can be performed in selected patients followed by adjuvant platinum-based chemotherapy. Concurrent chemoradiotherapy is also an option for NEC of the lung, rectum, and esophagus. In metastatic NEC, chemotherapy is administered with a classic combination of platinum salts and etoposide in the first-line setting. Peptide receptor radionuclide therapy (PRRT) has shown positive results in high-grade NEN populations and immunotherapy trials are still ongoing. Available therapies have improved the overall survival of NEC but there is still an urgent need for improvement. This narrative review sums up the current data on digestive NEC while exploring future directions for their management.
Collapse
|
2
|
Peng K, Cao H, You Y, He W, Jiang C, Wang L, Jin Y, Xia L. Optimal Surgery Type and Adjuvant Therapy for T1N0M0 Lung Large Cell Neuroendocrine Carcinoma. Front Oncol 2021; 11:591823. [PMID: 33868992 PMCID: PMC8044817 DOI: 10.3389/fonc.2021.591823] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 03/05/2021] [Indexed: 11/19/2022] Open
Abstract
Background The appropriate treatment strategy for T1N0M0 lung large cell neuroendocrine carcinoma (LCNEC) was not well illustrated. We evaluated the efficacy of different surgery types and adjuvant therapy on patients with T1N0M0 LCNEC. Methods Patients diagnosed T1N0M0 LCNEC from 2004 to 2016 were identified in the surveillance, epidemiology, and end results (SEER) database. Clinical characteristics, treatment and survival data were collected. The efficacy of surgery type and adjuvant therapy stratified by tumor size was assessed. Overall survival(OS) was evaluated by the Kaplan-Meier method, and relevant survival variables were identified by the Cox proportional hazard model. Results From 2004 to 2016, 425 patients were included in this study, 253 (59.5%) patients received lobectomy, and 236 (55.5%) patients had 4 or more lymph nodes removed. Patients received lobectomy had better survival than those received sublobar resection(P=0.000). No matter tumor size less than 2 cm or 2 to 3 cm, lobectomy was significantly prolonged survival. Compared with no lymph nodes removed, lymph nodes dissection was associated with more remarkable OS(P<0.000). 4 or more regional lymph nodes dissection predicted better OS compared with 1 to 3 regional lymph nodes dissection(P=0.014). After surgery, adjuvant chemotherapy did not contribute to extended survival in patients with tumor less than 2 cm(P=0.658), and possibly for tumor 2 to 3 cm(P=0.082). Multivariate analysis showed that age and lobectomy were independent prognostic factors(P=0.000). Conclusion Our results suggest that lobectomy and lymph nodes dissection were associated with significantly better survival. Extensive regional lymph node dissection(4 or more) was more effective in prolonging survival than 1 to 3 lymph nodes dissection. Adjuvant chemotherapy was not associated with extended survival for tumor less than 2 cm, and possibly for tumor 2 to 3 cm.
Collapse
Affiliation(s)
- Kunwei Peng
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Huijiao Cao
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yafei You
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Wenzhuo He
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Chang Jiang
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Lei Wang
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Yanan Jin
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Liangping Xia
- VIP Region, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| |
Collapse
|
3
|
Chen Y, Zhang J, Huang C, Tian Z, Zhou X, Guo C, Liu H, Li S. Survival outcomes of surgery in patients with pulmonary large-cell neuroendocrine carcinoma: a retrospective single-institution analysis and literature review. Orphanet J Rare Dis 2021; 16:82. [PMID: 33579331 PMCID: PMC7881654 DOI: 10.1186/s13023-021-01730-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Accepted: 02/03/2021] [Indexed: 01/08/2023] Open
Abstract
Background Pulmonary large-cell neuroendocrine carcinoma (pLCNEC) is a very rare malignancy originating from the lung and bronchus, and its biological behaviour, clinical diagnosis, treatment and prognosis are poorly understood. Thus, the clinical characteristics and surgical treatment-related prognostic factors of this rare disorder must be explored. Results The clinical data of 59 patients (48 males and 11 females) who were treated by surgery and diagnosed with pLCNEC by postoperative pathology at Peking Union Medical College Hospital from April 2004 to April 2019 were analysed retrospectively. The median patient age was 62 years (38–79 years), and the median duration of disease was 2 months (0.5–18 months). Compared with other lung malignancies, pLCNEC lacks specific clinical symptoms and imaging features, and preoperative biopsy pathology is often insufficient to confirm the diagnosis. The corresponding numbers of patients who were classified into stages I, II, III and IV according to the postoperative pathological tumour-nodal-metastasis stage were 25, 12, 15 and 7, respectively. The median overall survival was 36 months (0.9–61.1 months). The 1-year, 3-year and 5-year survival rates were 76.3%, 49% and 44.7%, respectively. The tumour stage exerted a significant effect on survival (Cox multivariate analysis p < 0.05). Conclusions For patients with resectable pLCNEC, multidisciplinary therapy based on surgery may have good survival benefits, and tumour stage is an independent risk factor for the prognosis of pLCNEC.
Collapse
Affiliation(s)
- Yeye Chen
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Jiaqi Zhang
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Cheng Huang
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Zhenhuan Tian
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Xiaoyun Zhou
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Chao Guo
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Hongsheng Liu
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
| | - Shanqing Li
- Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
| |
Collapse
|
4
|
Hadoux J, Blanchard P, Scoazec JY, Burtin P, Planchard D, Malka D, Berdelou A, Boige V, Duvillard P, Leboulleux S, Faron M, Tselikas L, Deutsch E, Ducreux M, Baudin E. Post-Radiation Grade 3 Neuroendocrine Carcinoma: A New Entity? Neuroendocrinology 2021; 111:139-145. [PMID: 31639792 DOI: 10.1159/000504255] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2019] [Accepted: 10/21/2019] [Indexed: 11/19/2022]
Abstract
BACKGROUND Cancer survivors have a 14% increased risk of developing a malignancy compared with the general population. Second radiation-induced malignancies with different histologies have been described in different organs. Based on individual observations, we hypothesized that neuroendocrine carcinoma (NEC) could arise in irradiated organs. METHODS In a retrospective analysis of Gustave Roussy database of NEC patients (small cell lung cancer excluded) diagnosed as a second cancer, we looked for the frequency of grade 3 NEC that arose in patients who had received previous radiation therapy for a first cancer. Radiation therapy for the first cancer, dose, location of radiation therapy, pathological characteristics, overall survival, and response to treatment of secondary NEC were analyzed. RESULTS From January 1995 to December 2017, 847 cases of NEC were seen at Gustave Roussy. Among them, 95 (11.2%) patients had a history of previous malignancy of which 36 (4%) had been treated with radiation therapy. Out of these 36 patients, 12 (1.4% of all NEC patients) developed a NEC within the previous irradiated organ (median dose of 50 Gy, range 36-67.5). Most frequent first cancers were breast cancer (n = 4) and Hodgkin lymphoma (n = 3). NEC arose within a median time of 21.7 years (range 5.1-36.4) from radiation in the thorax (n = 5), digestive tract (n = 3), and other sites. Five large cell NEC, 3 small cell NEC, 1 mixed neuroendocrine neoplasm and 3 not otherwise specified NEC were diagnosed. Ten patients had stage IV disease at diagnosis; median overall survival was 37.8 months (95% CI [17.6 to NA]). Three patients (25%) achieved complete response with multimodal treatment. CONCLUSIONS NEC can arise from previously irradiated organs and may have a better outcome in this setting. Other risk factors should be investigated to explain the high rate of previous cancer in this population of neuroendocrine neoplasm.
Collapse
Affiliation(s)
- Julien Hadoux
- Département d'Imagerie, Service d'Oncologie Endocrinienne, Université Paris-Saclay, Villejuif, France
| | - Pierre Blanchard
- Département de Radiothérapie, Université Paris-Saclay, Villejuif, France
| | - Jean-Yves Scoazec
- Département de Biologie et Pathologie Médicale, Université Paris-Saclay, Villejuif, France
| | - Pascal Burtin
- Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France
| | - David Planchard
- Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France
| | - David Malka
- Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France
| | - Amandine Berdelou
- Département d'Imagerie, Service d'Oncologie Endocrinienne, Université Paris-Saclay, Villejuif, France
| | - Valérie Boige
- Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France
| | - Pierre Duvillard
- Département de Biologie et Pathologie Médicale, Université Paris-Saclay, Villejuif, France
| | - Sophie Leboulleux
- Département d'Imagerie, Service d'Oncologie Endocrinienne, Université Paris-Saclay, Villejuif, France
| | - Matthieu Faron
- Département de Chirurgie Oncologique, Université Paris-Saclay, Villejuif, France
| | - Lambros Tselikas
- Département d'Imagerie, Service de Radiologie Interventionnelle, Université Paris-Saclay, Villejuif, France
| | - Eric Deutsch
- Département de Radiothérapie, Université Paris-Saclay, Villejuif, France
| | - Michel Ducreux
- Département de Médecine Oncologique, Université Paris-Saclay, Villejuif, France
| | - Eric Baudin
- Département d'Imagerie, Service d'Oncologie Endocrinienne, Université Paris-Saclay, Villejuif, France,
| |
Collapse
|
5
|
Sonbol MB, Halfdanarson TR. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Curr Treat Options Oncol 2019; 20:74. [PMID: 31428952 DOI: 10.1007/s11864-019-0670-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OPINION STATEMENT In 2017, the World Health Organization (WHO) classification for pancreatic NET was updated to include a new category of well-differentiated high-grade (Ki 67 > 20%) pancreatic tumors (NET G3), distinct from high-grade poorly differentiated neuroendocrine carcinoma (NEC). NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2. The optimal first-line management in NET G3 and sequencing therapies remains a challenge awaiting future trials taking into consideration the unique characteristics of this category. In this review, we aim to summarize the current evidence in the management of NET G3.
Collapse
|
6
|
Yang Q, Xu Z, Chen X, Zheng L, Yu Y, Zhao X, Chen M, Luo B, Wang J, Sun J. Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. Thorac Cancer 2019; 10:751-760. [PMID: 30734490 PMCID: PMC6449250 DOI: 10.1111/1759-7714.12993] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2018] [Revised: 01/06/2019] [Accepted: 01/07/2019] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND The study was conducted to compare the clinicopathological characteristics, survival outcomes, and metastatic patterns between pulmonary large cell neuroendocrine carcinoma (LCNEC) and other non-small cell lung cancer (ONSCLC), and to identify the prognostic factors of LCNEC. METHODS Data of patients diagnosed with LCNEC and ONSCLC from 2004 to 2014 were obtained from the Surveillance, Epidemiology, and End Results dataset. Pearson's chi-square tests were used to compare differences in clinicopathological characteristics. The Kaplan-Meier method was used for survival analysis. A propensity score was used for matching and a Cox proportional hazards model was used for multivariate and subgroup analyses. RESULTS A total of 2368 LCNEC cases and 231 672 ONSCLC cases were identified. LCNEC incidence increased slightly over time. Except for marital status, LCNEC patients had obviously different biological features to ONSCLC patients. Survival analysis showed that LCNEC had poorer outcomes than ONSCLC. Multivariate analysis revealed that female gender, black race, surgery, radiation, and chemotherapy were protective factors for LCNEC. Matched subgroup analysis further demonstrated that most subgroup factors favored ONSCLC, especially in early stage. Early-stage LCNEC patients had a higher risk of lung cancer-specific death than early-stage ONSCLC patients. Moreover, metastatic patterns were different between LCNEC and ONSCLC. LCNEC patients with isolated liver metastasis or combined invasion to other organs had poorer survival rates. CONCLUSIONS LCNEC has totally different clinicopathological characteristics and metastatic patterns to ONSCLC. LCNEC also has poorer survival outcomes, primarily because of isolated liver metastasis or combined invasion to other organs. Most subgroup factors are adverse factors for LCNEC.
Collapse
Affiliation(s)
- Qiao Yang
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Zihan Xu
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Xiewan Chen
- Medical English Department, College of Basic Medicine, Army Medical University, Chongqing, China
| | - Linpeng Zheng
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Yongxin Yu
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Xianlan Zhao
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Mingjing Chen
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Bangyu Luo
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Jianmin Wang
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| | - Jianguo Sun
- Cancer Institute of People's Liberation Army, Xinqiao Hospital, Army Medical University, Chongqing, China
| |
Collapse
|
7
|
Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocr Relat Cancer 2018; 25:R375-R384. [PMID: 29669844 DOI: 10.1530/erc-17-0507] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Accepted: 04/18/2018] [Indexed: 12/12/2022]
Abstract
The recent recognition that grade 3 (G3) neuroendocrine neoplasms (NENs) can be divided into two different categories according to the histopathological differentiation, that is G3 neuroendocrine tumors (NETs) and G3 neuroendocrine carcinomas (NECs) has generated a lot of interest concerning not only the diagnosis, but also the differential management of such new group of NENs. However, several issues need to be fully clarified in order to put G3 NETs and G3 NECs in the right place. The aim of this review is to focus on those issues that are still undetermined starting from the current knowledge, evaluating the available evidence and the possible clinical implications.
Collapse
Affiliation(s)
- Maria Chiara Zatelli
- Department of Medical SciencesSection of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy
| | - Elia Guadagno
- Department of Advanced Biomedical SciencesPathology Section, University of Naples Federico II, Naples, Italy
| | - Erika Messina
- Department of Clinical and Experimental MedicineUniversity of Messina, Messina, Italy
| | - Fabio Lo Calzo
- Department of Clinical Medicine and SurgeryFederico II University, Naples, Italy
| | - Antongiulio Faggiano
- Department of Clinical Medicine and SurgeryFederico II University, Naples, Italy
| | - Annamaria Colao
- Department of Clinical Medicine and SurgeryFederico II University, Naples, Italy
| | | |
Collapse
|
8
|
New insights into hypoxia-related mechanisms involved in different microvascular patterns of bronchopulmonary carcinoids and poorly differentiated neuroendocrine carcinomas. Role of ribonuclease T2 (RNASET2) and HIF-1α. Hum Pathol 2018; 79:66-76. [PMID: 29763721 DOI: 10.1016/j.humpath.2018.04.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 04/10/2018] [Accepted: 04/24/2018] [Indexed: 02/08/2023]
Abstract
Ribonuclease T2 (RNASET2) is a pleiotropic and polyfunctional protein, which exerts several different activities in neoplastic cells since the early steps of tumor development. Besides having an antitumorigenic activity, RNASET2 inhibits both bFGF-induced and VEGF-induced angiogenesis and has a role as a stress-response, alarmin-like, protein. In this study, we investigated RNASET2 expression in well-differentiated and poorly differentiated neuroendocrine neoplasms of the lung (Lu-NENs), which are known to show clear-cut differences in morphology, biology and clinical behavior. In addition, we explored possible relationships between RNASET2 expression and a series of immunohistochemical markers related to hypoxic stress, apoptosis, proliferation and angiogenesis. Our results showed a significantly higher expression of RNASET2, HIF-1α, and its target CA IX in poorly differentiated than in well-differentiated Lu-NENs, the former also showing higher proliferation and apoptotic rates, as well as a lower microvessel density (MVD) than the latter. Moreover, we were able to demonstrate in vitro an overexpression of RNASET2 in consequence of the activation of HIF-1α. In conclusion, we suggest that in poorly differentiated Lu-NENs, RNASET2 expression may be induced by HIF-1α, behaving as an alarmin-like molecule. In this aggressive group of cancers, which have highly deregulated proliferation pathways, RNASET2 fails to exert the growth-inhibiting effects described in other types of neoplasms. Its increased expression, however, may contribute to the typical phenotypic alterations seen in poorly differentiated Lu-NENs, such as the high apoptotic rate and the extensive necrosis, and may also enhance the low MVD observed in these neoplasms.
Collapse
|
9
|
Ogura J, Adachi Y, Yasumoto K, Okamura A, Nonogaki H, Kakui K, Yamanoi K, Suginami K, Koyama T, Ikehara S. Large-cell neuroendocrine carcinoma arising in the endometrium: A case report. Mol Clin Oncol 2018; 8:571-574. [PMID: 29564132 DOI: 10.3892/mco.2018.1583] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 01/17/2018] [Indexed: 12/15/2022] Open
Abstract
Large-cell neuroendocrine carcinoma (LCNEC) of the endometrium is an extremely rare, high-grade malignant tumor. We herein report a case of a rapidly growing LCNEC arising in the endometrium. A 52-year-old woman was referred to Toyooka Hospital (Tooyoka, Japan) due to genital bleeding in February 2016. There had been no abnormalities on a regular gynecological and physical examination 3 months prior to the consultation. Imaging (computed tomography and magnetic resonance imaging) and a pelvic examination revealed a tumor sized 16.9×8.4×7.8 mm occupying the intrauterine cavity and extending into the vaginal cavity. Multiple metastatic pelvic and paraaortic lymph nodes were also identified. Continuous bleeding from the tumor was observed, and a blood examination revealed anemia, which was likely due to that bleeding. Biopsy of the tumor was performed, and large atypical cells were identified. The tumor cells were negative for cytokeratin AE1/AE3 and chromogranin A, but positive for CD56 and synaptophysin. There was also an abundance of Ki-67-positive cells in the tumor, altogether suggesting that the tumor was an LCNEC. The patient succumbed to the disease 36 days after the first consultation. Based on the findings of the present case and previously published cases, LCNECs arising in the endometrium may progress rapidly and are associated with an unfavourable outcome. LCNEC should be included in the differential diagnosis in cases of rapidly growing tumors of the uterine corpus.
Collapse
Affiliation(s)
- Jumpei Ogura
- Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan.,Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Kyoto 606-8501, Japan
| | - Yasushi Adachi
- Department of Diagnostic Pathology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan
| | - Koji Yasumoto
- Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan.,Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Kyoto 606-8501, Japan
| | - Akiharu Okamura
- Department of Diagnostic Pathology, Kakogawa Central City Hospital, Kakogawa, Hyogo 675-8611, Japan
| | - Hirofumi Nonogaki
- Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan
| | - Kazuyo Kakui
- Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan.,Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Kyoto 606-8501, Japan
| | - Koji Yamanoi
- Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan.,Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Kyoto 606-8501, Japan
| | - Koh Suginami
- Department of Obstetrics and Gynecology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan.,Department of Obstetrics and Gynecology, Kyoto University, Kyoto, Kyoto 606-8501, Japan
| | - Takashi Koyama
- Department of Radiology, Toyooka Hospital, Toyooka, Hyogo 668-8501, Japan
| | - Susumu Ikehara
- Professor Emeritus, Kansai Medical University, Hirakata, Osaka 573-1010, Japan
| |
Collapse
|
10
|
Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017; 79:158-165. [PMID: 28501762 DOI: 10.1016/j.ejca.2017.04.009] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2016] [Revised: 04/05/2017] [Accepted: 04/06/2017] [Indexed: 12/13/2022]
Abstract
BACKGROUND Diagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging. Recent studies suggest prognostic heterogeneity. We designed within the French Group of Endocrine Tumours a prospective cohort to gain insight in the prognostic stratification and treatment of GEP-NEC. PATIENTS AND METHODS All patients with a diagnosis of GEP-NEC between 1st January 2010 and 31st December 2013 could be included in this national cohort. Adenoneuroendocrine tumours were excluded. RESULTS 253 patients from 49 centres were included. Median age was 66 years. Main primary locations were pancreas (21%), colorectal (27%), oesophagus-stomach (18%); primary location was unknown in 20%. Tumours were metastatic at diagnosis in 78% of cases. Performance status (PS) at diagnosis was 0-1 in 79% of patients. Among the 147 (58%) cases reviewed by an expert pathological network, 39% were classified as small cell NEC and 61% as large cell NEC. Median Ki67 index was 75% (range, 20-100). Median overall survival was 15.6 (13.6-17.0) months. Significant adverse prognostic factors in univariate analysis were PS > 1 (hazard ratio [HR] = 2.5), metastatic disease (HR = 1.6), NSE>2 upper limit of normal [ULN]; HR = 3.2), CgA>2 ULN (HR = 1.7) and lactate dehydrogenase >2 ULN (HR = 2.1). After first-line palliative chemotherapy (CT1) with platinum-etoposide (n = 152), objective response, progression-free survival and overall survival were 50%, 6.2 and 11.6 months; they were 24%, 2.9 and 5.9, respectively, after post-CT1 FOLFIRI regimen (n = 72). CONCLUSIONS We report a large prospective series of GEP-NEC which show the predominance of large cell type and advanced stage at diagnosis. Prognosis was found more homogeneous than previously reported, mainly impacted by PS and tumour burden.
Collapse
Affiliation(s)
- T Walter
- University Hospital, Lyon, France.
| | | | - E Baudin
- Gustave Roussy Institute, Villejuif, France
| | | | | | - D Malka
- Gustave Roussy Institute, Villejuif, France
| | - O Hentic
- Beaujon Hospital, Clichy, France
| | | | - I Bonnet
- Valenciennes Hospital, Valenciennes, France
| | | | - R Coriat
- Cochin Hospital, University Paris Descartes, Paris, France
| | - C Lepère
- Georges Pompidou European Hospital, University Paris-V, Paris, France
| | - C Desauw
- University Hospital, Lille, France
| | | | - L Dahan
- La Timone Hospital, Marseille, France
| | - G Roquin
- University Hospital, Angers, France
| | | | | | | | | | - C Lepage
- FFCD, Dijon, France; University Hospital, Dijon, France
| | - G Cadiot
- University Hospital, Reims, France
| | | |
Collapse
|
11
|
Zhu J, Yang Y, Liu S, Xu H, Wu Y, Zhang G, Wang Y, Wang Y, Liu Y, Guo Q. Anticancer effect of thalidomide in vitro on human osteosarcoma cells. Oncol Rep 2016; 36:3545-3551. [PMID: 27748909 DOI: 10.3892/or.2016.5158] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 09/05/2016] [Indexed: 11/06/2022] Open
Abstract
Osteosarcoma is a high‑grade malignant tumor frequently found in children and adolescents. Thalidomide has been reported for treatment of various malignancies. Thalidomide was added to osteosarcoma cells and studied by cytotoxicity assay, evaluating apoptosis, cell cycle arrest, mitochondrial membrane potential (ΔΨm), and reactive oxygen species (ROS) levels and the expression of Bcl‑2, Bax, caspase‑3 and NF‑κB. The results showed that thalidomide could inhibit the proliferation of MG‑63 and U2OS cells in a concentration‑ and time‑dependent manner. Morphological changes of apoptosis were also observed. Thalidomide increased the apoptosis rate of MG‑63 cells and induced cell cycle arrest by increasing the number of cells in the G0/G1 phase and decreasing the percentage of S phase in MG‑63 cells. Further investigation showed that a disruption of ΔΨm and upregulation of ROS were induced by thalidomide in high concentration. By western blot analysis, thalidomide resulted in the decreasing expression of Bcl‑2 and NF‑κB, and the increasing expression of Bcl‑2/Bax and caspase‑3. Here, we provide evidence that thalidomide could cause apoptosis in osteosarcoma cells. Taken together, these results indicate that thalidomide could be an antitumor drug in the therapy of osteosarcoma.
Collapse
Affiliation(s)
- Jianwei Zhu
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Ya Yang
- The Nursing College, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
| | - Sihong Liu
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Huihua Xu
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Yong Wu
- Department of Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Guiqiang Zhang
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Yuxuan Wang
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Yan Wang
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Yamin Liu
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| | - Qifeng Guo
- Department of Orthopaedics, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China
| |
Collapse
|
12
|
Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist 2016; 21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Citation(s) in RCA: 105] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Accepted: 03/21/2016] [Indexed: 02/07/2023] Open
Abstract
: In 2010, the World Health Organization (WHO) classification of neuroendocrine neoplasms was reviewed and validated the crucial role of the proliferative rate. According to the WHO classification 2010, gastroenteropancreatic neuroendocrine neoplasms are classified as well-differentiated neuroendocrine tumors (NETs) of grade 1 or 2 in up to 84%, or poorly differentiated neuroendocrine carcinomas in 6%-8%. Neuroendocrine carcinomas are of grade G. Recently, a proportion of neuroendocrine tumors presenting a number of mitoses or a Ki-67 index higher than 20% and a well-differentiated morphology have been identified, calling for a new category, well-differentiated grade 3 NET (NET G-3). Studies that have reported the characteristics of neuroendocrine neoplasms have identified more well-differentiated NET G-3 than neuroendocrine carcinomas. The main localizations of NET G-3 are the pancreas, stomach, and colon. Treatment for NET G-3 is not standardized and is balanced between G-1/2 neuroendocrine tumor and neuroendocrine carcinoma treatments. In nonmetastatic neuroendocrine tumors, the European and American guidelines recommended a surgical resection for localized neuroendocrine neoplasm, irrespective of the tumor grading. In NET G-3, chemotherapy is the benchmark if the main treatment goal is reduction of the tumor mass, particularly if it would allow a secondary surgery. In the present work, we review the epidemiology and make recommendations for the management of NET G-3. IMPLICATIONS FOR PRACTICE Neuroendocrine tumors presenting a number of mitoses or a Ki-67 index higher than 20% and a well-differentiated morphology have been identified and named well-differentiated grade 3 neuroendocrine tumors (NET G-3). The main localizations of NET G-3 are the pancreas, stomach, and colon. The prognosis is worse than that for NET G-2. In nonmetastatic NET G-3, surgery appeared to be the first option. The chemotherapy regimen in pancreatic NET G-3 should be in line with that implemented in NET G-1/2 when the Ki-67 index is below 55% and should be in line with that implemented for neuroendocrine carcinoma when Ki-67 is above 55%.
Collapse
Affiliation(s)
- Romain Coriat
- Department of Gastroenterology, Cochin Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Thomas Walter
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Oncologie Digestive, Lyon Cedex 03, France Université Claude Bernard Lyon 1, Université de Lyon, , Lyon, France
| | - Benoît Terris
- Department of Pathology, Cochin Teaching Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Anne Couvelard
- Department of Pathology, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Départements Hospitalo Universitaires, Paris, France Department of Gastroenterology and Pancreatology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Départements Hospitalo Universitaires, Clichy, France
| | - Philippe Ruszniewski
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France Department of Gastroenterology and Pancreatology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, Départements Hospitalo Universitaires, Clichy, France
| |
Collapse
|
13
|
Metastatic large cell neuroendocrine carcinoma of the lung arising from the uterus: A pitfall in lung cancer diagnosis. Pathol Res Pract 2016; 212:654-7. [PMID: 27113439 DOI: 10.1016/j.prp.2016.03.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Revised: 03/02/2016] [Accepted: 03/21/2016] [Indexed: 12/29/2022]
Abstract
A 41-year-old female smoker presented with a vaginal mass. Gynecological examination showed a mass filling the uterine corpus, cervix, and vagina. A total abdominal hysterectomy was performed. Macroscopic findings included a large fragile mass involving the uterine cavity, cervix, and vagina. Histology revealed atypical ducts admixed with solid components consisting of large atypical cells. The initial pathological diagnosis was grade 3 endometrioid adenocarcinoma. The patient was designated as stage II according to the 2008 International Federation of Gynecology and Obstetrics (FIGO) staging. Two years later, two nodules were found in the upper lobe of the left lung, and the patient underwent an upper lobectomy. The masses, which exhibited solid and organoid growth patterns of large atypical cells, had histological characteristics of large cell neuroendocrine carcinoma (LCNEC) of the lung. However, the tumor was immunohistochemically positive for neuroendocrine markers, such as synaptophysin in addition to estrogen receptor and progesterone receptor, and the tumor was negative for thyroid transcription factor-1. These immunohistochemical results were almost identical to those of the solid portions of the uterine carcinoma. The final diagnosis was LCNEC combined with endometrioid adenocarcinoma of the uterine corpus and lung metastasis of the LCNEC component of the endometrial carcinoma. LCNEC often arises in the lung, but it rarely arises in other organs. Some patients with metastatic components exhibited only a LCNEC pattern although the primary tumor was a mixed carcinoma consisting of LCNEC and other histology, like the present case. LCNEC is often poorly differentiated, especially in extrapulmonary primary organ LCNEC. Therefore, pathologists should consider metastatic carcinoma when they encounter lung LCNEC in a patient with a preceding extrapulmonary carcinoma composed of a poorly differentiated component or LCNEC component, and they should clarify tumor immunohistochemical characteristics to confirm the diagnosis.
Collapse
|
14
|
Hadoux J, Malka D, Planchard D, Scoazec JY, Caramella C, Guigay J, Boige V, Leboulleux S, Burtin P, Berdelou A, Loriot Y, Duvillard P, Chougnet CN, Déandréis D, Schlumberger M, Borget I, Ducreux M, Baudin E. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015; 22:289-98. [PMID: 25770151 DOI: 10.1530/erc-15-0075] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/11/2015] [Indexed: 12/13/2022]
Abstract
There is no standard for second-line chemotherapy in poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC) patients. We analyzed the antitumor efficacy of 5-fluorouracil and oxaliplatin (FOLFOX) chemotherapy in this population. A single-center retrospective analysis of consecutive G3-NEC patients treated with FOLFOX chemotherapy after failure of a cisplatinum-based regimen between December 2003 and June 2012 was performed. Progression-free survival (PFS), overall survival (OS), response rate, and safety were assessed according to RECIST 1.1 and NCI.CTC v4 criteria. Twenty consecutive patients were included (seven males and 13 females; median age 55; range 23-87 years) with a performance status of 0-1 in 75% of them. Primary location was gastroenteropancreatic in 12, thoracic in four, other in two, and unknown in two patients. There were 12 (65%) large-cell and 7 (30%) small-cell G3-NEC tumors, and 1 (5%) unknown. All patients had distant metastases. Twelve (60%) patients received FOLFOX as second-line treatment and 8 (40%) as third-line treatment or later and the median number of administered cycles was 6 (range 3-14). The median follow-up was 19 months. Median PFS was 4.5 months. Among the 17 evaluable patients, five partial responses (29%), six stable diseases (35%), and six progressive diseases (35%) were observed. Median OS was 9.9 months. Main Grade 3-4 toxicities were neutropenia (35%), thrombopenia (20%), nausea/vomiting (10%), anemia (10%), and elevated liver transaminases (10%). Our results indicate that the FOLFOX regimen could be considered as a second-line option in poorly differentiated G3-NEC patients after cisplatinum-based first-line treatment but warrant further confirmation in future larger prospective studies.
Collapse
Affiliation(s)
- J Hadoux
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - D Malka
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - D Planchard
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - J Y Scoazec
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - C Caramella
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - J Guigay
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - V Boige
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - S Leboulleux
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - P Burtin
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - A Berdelou
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - Y Loriot
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - P Duvillard
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - C N Chougnet
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - D Déandréis
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - M Schlumberger
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - I Borget
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - M Ducreux
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| | - E Baudin
- Departments of Nuclear Medicine and Endocrine TumorsDigestive OncologyMedical Oncology (Thoracic Group)PathologyRadiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceCentre Antoine LacassagneCLCC, 33, Avenue de Valombrose, F-06189 Nice, FranceDepartment of Urologic OncologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceDepartment of EndocrinologyHôpital Saint Louis - APHP, 1, Avenue Claude-Vellefaux, F-75010 Paris, FranceDepartment of Biostatistics and EpidemiologyGustave Roussy, 114 Rue Edouard Vaillant, F-94800 Villejuif Cedex, FranceFaculté de MédecineParis-Sud University, F-94270 Le Kremlin Bicêtre, France
| |
Collapse
|
15
|
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) 2015; 5:119-76. [PMID: 26854147 PMCID: PMC4665594 DOI: 10.3390/diagnostics5020119] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Revised: 03/24/2015] [Accepted: 03/26/2015] [Indexed: 02/07/2023] Open
Abstract
To date, empirical literature has generally been considered lacking in relation to neuroendocrine carcinomas (NECs), the highly malignant subgroup of neuroendocrine neoplasms. NECs are often found in the lungs or the gastroenteropancreatic (GEP) system and can be of small or large cell type. Concentrating on GEP-NECs, we can conclude that survival times are poor, with a median of only 4–16 months depending on disease stage and primary site. Further, this aggressive disease appears to be on the rise, with incidence numbers increasing while survival times are stagnant. Treatment strategies concerning surgery are often undecided and second-line chemotherapy is not yet established. After an analysis of over 2600 articles, we can conclude that there is indeed more empirical literature concerning GEP-NECs available than previously assumed. This unique review is based on 333 selected articles and contains detailed information concerning all aspects of GEP-NECs. Namely, the classification, histology, genetic abnormalities, epidemiology, origin, biochemistry, imaging, treatment and survival of GEP-NECs are described. Also, organ-specific summaries with more detail in relation to disease presentation, diagnosis, treatment and survival are presented. Finally, key points are discussed with directions for future research priorities.
Collapse
|
16
|
|
17
|
Large cell neuroendocrine carcinoma of the rectum presenting with extensive metastatic disease. Case Rep Oncol Med 2014; 2014:386379. [PMID: 25225617 PMCID: PMC4124645 DOI: 10.1155/2014/386379] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2014] [Accepted: 07/04/2014] [Indexed: 11/18/2022] Open
Abstract
Introduction. Rectal large cell neuroendocrine carcinoma (LCNEC) is a poorly differentiated neoplasm that is very rare and belongs within the poorest prognostic subgroup among primary colorectal neoplasms. Here, we describe a case of LCNEC of the rectum, which highlights the aggressive clinical course and poor prognosis associated with this disease. Case Presentation. We report a case of a 63-year-old male who presented to our hospital with a one-month history of lower abdominal pain, constipation, and weight loss. A computed tomography (CT) scan of the chest, abdomen, and pelvis revealed a rectal mass as well as metastatic disease of the liver and lung. Flexible sigmoidoscopy revealed a fungating, ulcerated and partially obstructing rectal mass located 6 cm from the anal verge. This mass was biopsied and pathological examination of the resected specimen revealed features consistent with a large cell neuroendocrine carcinoma. Conclusion. Rectal large cell neuroendocrine carcinomas are rare and have a significantly worse prognosis than adenocarcinomas. At diagnosis, a higher stage and metastatic disease are likely to be found. It is important to differentiate large cell, poorly differentiated neuroendocrine carcinomas from adenocarcinomas of the colon and rectum pathologically because patients may benefit from alternative cytotoxic chemotherapeutic regimens.
Collapse
|
18
|
Suleiman M, Mullane M. Oligometastatic Large Cell Neuroendocrine Carcinoma of the Brain Without Radiologically Detected Primary. World J Oncol 2014; 5:135-138. [PMID: 29147392 PMCID: PMC5649817 DOI: 10.14740/wjon805w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/08/2014] [Indexed: 11/11/2022] Open
Abstract
A 60-year-old Polish male was admitted into our hospital with complaint of right-sided lower extremity weakness. CT of head showed a left frontal 2.6 × 1.5 cm mass. Staging work-up did not show any other associated lesions in the chest or abdomen. Brain tumor was resected with histology consistent with large cell neuroendocrine carcinoma with most likely lung primary because of TTF-1 positivity. Following recovery from surgery, he had external beam radiation therapy to the brain and systemic chemotherapy with four cycles of cisplatin/etoposide. Patient is alive and doing well 6 months post diagnosis with no evidence of recurrence.
Collapse
Affiliation(s)
- Moyosore Suleiman
- Department of Hematology and Oncology, John H Stroger Jr Hospital of Cook County, Chicago, IL 60612, USA
| | - Michael Mullane
- Department of Hematology and Oncology, John H Stroger Jr Hospital of Cook County, Chicago, IL 60612, USA
| |
Collapse
|
19
|
Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014; 120:2814-23. [PMID: 24771552 DOI: 10.1002/cncr.28721] [Citation(s) in RCA: 235] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2014] [Revised: 03/17/2014] [Accepted: 03/19/2014] [Indexed: 12/15/2022]
Abstract
Gastroenteropancreatic (GEP) neuroendocrine neoplasms are classified as low-grade, intermediate-grade, and high-grade tumors based on morphologic criteria and the proliferation rate. Most studies have been conducted in patients with well differentiated (low-grade to intermediate-grade) neuroendocrine tumors. Data are substantially scarcer on poorly differentiated, high-grade neuroendocrine carcinoma (NEC), which includes the entities of small cell carcinoma and large cell NEC. A literature search of GEP-NEC was performed. Long-term survival was poor even among patients who presented with localized disease. Several studies highlighted heterogeneity within the high-grade NEC category and a need for the further identification of discreet prognostic and predictive groups. Tumors with a Ki-67 proliferation index <55% were less responsive to platinum-based chemotherapy, and patients with such tumors or with well differentiated morphology had better survival than patients who had tumors with poorly differentiated morphology or a higher Ki-67 index. Treatment options beyond platinum-based chemotherapy are emerging. A revision of the World Health Organization high-grade NEC classification seems to be necessary based on recent data. Platinum-based chemotherapy may not be the optimal treatment for patients who have GEP-NEC with a moderately high proliferation rate. Adequate diagnostic and prognostic stratifications constitute the basis for future progress.
Collapse
Affiliation(s)
- Halfdan Sorbye
- Department of Oncology, Haukeland University Hospital, Bergen, Norway
| | | | | | | | | |
Collapse
|
20
|
Basturk O, Tang L, Hruban RH, Adsay NV, Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL, Liu X, Zhang L, Giordano TJ, Bellizzi AM, Chen JH, Shi C, Allen P, Reidy DL, Wolfgang CL, Saka B, Rezaee N, Deshpande V, Klimstra DS. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol 2014; 38:437-47. [PMID: 24503751 PMCID: PMC3977000 DOI: 10.1097/pas.0000000000000169] [Citation(s) in RCA: 167] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND In the pancreas, poorly differentiated neuroendocrine carcinomas include small cell carcinoma and large cell neuroendocrine carcinoma and are rare; data regarding their pathologic and clinical features are very limited. DESIGN A total of 107 pancreatic resections originally diagnosed as poorly differentiated neuroendocrine carcinomas were reassessed using the classification and grading (mitotic rate/Ki67 index) criteria put forth by the World Health Organization in 2010 for the gastroenteropancreatic system. Immunohistochemical labeling for neuroendocrine and acinar differentiation markers was performed. Sixty-three cases were reclassified, mostly as well-differentiated neuroendocrine tumor (NET) or acinar cell carcinoma, and eliminated. The clinicopathologic features and survival of the remaining 44 poorly differentiated neuroendocrine carcinomas were further assessed. RESULTS The mean patient age was 59 years (range, 21 to 82 y), and the male/female ratio was 1.4. Twenty-seven tumors were located in the head of the pancreas, 3 in the body, and 11 in the tail. The median tumor size was 4 cm (range, 2 to 18 cm). Twenty-seven tumors were large cell neuroendocrine carcinomas, and 17 were small cell carcinomas (mean mitotic rate, 37/10 and 51/10 HPF; mean Ki67 index, 66% and 75%, respectively). Eight tumors had combined components, mostly adenocarcinomas. In addition, 2 tumors had components of well-differentiated NET. Eighty-eight percent of the patients had nodal or distant metastatic disease at presentation, and an additional 7% developed metastases subsequently. Follow-up information was available for 43 patients; 33 died of disease, with a median survival of 11 months (range, 0 to 104 mo); 8 were alive with disease, with a median follow-up of 19.5 months (range, 0 to 71 mo). The 2- and 5-year survival rates were 22.5% and 16.1%, respectively. CONCLUSIONS Poorly differentiated neuroendocrine carcinoma of the pancreas is a highly aggressive neoplasm, with frequent metastases and poor survival. Most patients die within less than a year. Most (61%) are large cell neuroendocrine carcinomas. Well-differentiated NET and acinar cell carcinoma are often misdiagnosed as poorly differentiated neuroendocrine carcinoma, emphasizing that diagnostic criteria need to be clearly followed to ensure accurate diagnosis.
Collapse
Affiliation(s)
- Olca Basturk
- Departments of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Laura Tang
- Departments of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Ralph H. Hruban
- Departments of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD
| | | | - Zhaohai Yang
- Departments of Pathology, Penn State Hershey MC, Hershey, PA
| | | | - Efsevia Vakiani
- Departments of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Stefano La Rosa
- Departments of Pathology, Ospedale di Circolo, Varese, Italy
| | - Kee-Taek Jang
- Departments of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | - Xiuli Liu
- Departments of Pathology, Cleveland Clinic, Cleveland, OH
| | - Lizhi Zhang
- Departments of Pathology, Mayo Clinic, Rochester, MN
| | | | - Andrew M. Bellizzi
- Departments of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA
| | - Jey-Hsin Chen
- Departments of Pathology, Indiana University, Indianapolis, IN
| | - Chanjuan Shi
- Departments of Pathology, Vanderbilt University, Nashville, TN
| | - Peter Allen
- Departments of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Diane L. Reidy
- Department of Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Christopher L. Wolfgang
- Departments of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD
- Departments of Surgery, The Johns Hopkins University, Baltimore, MD
| | - Burcu Saka
- Departments of Pathology, Emory University, Atlanta, GA
| | - Neda Rezaee
- Departments of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University, Baltimore, MD
- Departments of Surgery, The Johns Hopkins University, Baltimore, MD
| | - Vikram Deshpande
- Departments of Pathology, Massachusetts General Hospital, Boston, MA
| | - David S. Klimstra
- Departments of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
21
|
Anti-tumor effect of rutin on human neuroblastoma cell lines through inducing G2/M cell cycle arrest and promoting apoptosis. ScientificWorldJournal 2013; 2013:269165. [PMID: 24459422 PMCID: PMC3891239 DOI: 10.1155/2013/269165] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2013] [Accepted: 11/07/2013] [Indexed: 02/08/2023] Open
Abstract
AIMS To further investigate the antineuroblastoma effect of rutin which is a type of flavonoid. METHODS The antiproliferation of rutin in human neuroblastoma cells LAN-5 were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Chemotaxis of LAN-5 cells was assessed using transwell migration chambers and scratch wound migration assay. The cell cycle arrest and apoptosis in a dose-dependent manner was measured by flow cytometric and fluorescent microscopy analyses. The apoptosis-related proteins BAX and BCL2 as well as MYCN mRNA express were determined by RT-PCR analysis. Secreted TNF- α level were determined using specific enzyme-linked immunosorbent assay kits. RESULTS Rutin significantly inhibited the growth of LAN-5 cells and chemotactic ability. Flow cytometric analysis revealed that rutin induced G2/M arrest in the cell cycle progression and induced cell apoptosis. The RT-PCR showed that rutin could decrease BCL2 expression and BCL2/BAX ratio. In the meantime, the MYCN mRNA level and the secretion of TNF- α were inhibited. CONCLUSION These results suggest that rutin produces obvious antineuroblastoma effects via induced G2/M arrest in the cell cycle progression and induced cell apoptosis as well as regulating the expression of gene related to apoptosis and so on. It supports the viability of developing rutin as a novel therapeutic prodrug for neuroblastoma treatment, as well as providing a new path on anticancer effect of Chinese traditional drug.
Collapse
|
22
|
Vélayoudom-Céphise FL, Duvillard P, Foucan L, Hadoux J, Chougnet CN, Leboulleux S, Malka D, Guigay J, Goere D, Debaere T, Caramella C, Schlumberger M, Planchard D, Elias D, Ducreux M, Scoazec JY, Baudin E. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 2013; 20:649-57. [PMID: 23845449 DOI: 10.1530/erc-13-0027] [Citation(s) in RCA: 236] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The new WHO classification of gastroenteropancreatic (GEP) neuroendocrine tumors (NET) implies that G3 neoplasms with mitotic index >20 and/or Ki67 index >20% are neuroendocrine carcinomas (NEC), described as poorly differentiated, small or large cell types, by analogy with lung NEC. To characterize the subgroup of non-small-cell-type GEP and thoracic NET with mitotic index >20 and/or Ki67 >20% according to their pathological features, response to cisplatin and overall survival (OS). We reviewed pathological and clinical presentation of G3 non-small-cell-type NET referred to our institution for 5 years. Data from 166 patients with metastatic thoracic and GEP-NET were collected. Twenty-eight patients (17%) fulfill the inclusion criteria. Tumors were classified as well-differentiated NET (G3-WDNET) in 42.8% of cases and poorly differentiated, large-cell NEC (G3-LCNEC) in 57.2% of cases. Plasma chromogranin A or neuron-specific enolase were elevated in 42 and 25% respectively of G3-WDNET and 31 and 50% of G3-LCNEC. Somatostatin receptor scintigraphy was positive in 88 and 50% of G3-WDNET or G3-LCNEC respectively. Complete or partial response to cisplatin was observed in 31% of cases, all classified as G3-LCNEC. The median OS was 41 months for G3-WDNET but 17 months for G3-LCNEC (P=0.34). Short survival was observed in 25% of G3-WDNET but 62.5% of G3-LCNEC patients (P=0.049). G3 ENETS GEP and thoracic neuroendocrine neoplasms (NEN) could constitute a heterogeneous subgroup of NEN as regards diagnosis, prognosis, and treatment. If confirmed, future classifications may consider splitting them into two groups according to their morphological differentiation.
Collapse
|
23
|
Intervention in gastro-enteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26:855-65. [PMID: 23582924 DOI: 10.1016/j.bpg.2013.01.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2013] [Accepted: 01/24/2013] [Indexed: 01/31/2023]
Abstract
Neuroendocrine tumours require dedicated interventions to control their capacity to secrete hormones but also, antitumour growth strategies. Recommendations for early interventions in NET include the management of hormone-related symptoms and poorly differentiated neuroendocrine carcinomas. In contrast, prognostic heterogeneity is a key feature of well differentiated NET that complexified the antitumour strategy whatever the stage in this subgroup of tumour. In this review, timely therapeutic interventions to control hormone-related symptoms and tumour growth in GEP NET patients are discussed. The necessity of controlling hormone-related symptoms as the first step of any strategy affects also the tumour growth control strategy. In the absence of cure at the metastatic stage, progresses are expected in the recognition of well differentiated NET subgroups that display either excellent or poor prognosis.
Collapse
|
24
|
Faggiano A, Ferolla P, Grimaldi F, Campana D, Manzoni M, Davì MV, Bianchi A, Valcavi R, Papini E, Giuffrida D, Ferone D, Fanciulli G, Arnaldi G, Franchi GM, Francia G, Fasola G, Crinò L, Pontecorvi A, Tomassetti P, Colao A. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest 2012; 35:817-23. [PMID: 22080849 DOI: 10.3275/8102] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND The few epidemiological data available in literature on neuroendocrine tumors (NET) are mainly based on Registry databases, missing therefore details on their clinical and natural history. AIM To investigate epidemiology, clinical presentation, and natural history of NET. DESIGN AND SETTING A large national retrospective survey was conducted in 13 Italian referral centers. Among 1203 NET, 820 originating in the thorax (T-NET), in the gastro-enteropancreatic tract (GEP-NET) or metastatic NET of unknown primary origin (U-NET) were enrolled in the study. RESULTS 93% had a sporadic and 7% a multiple endocrine neoplasia type 1 (MEN1)-associated tumor; 63% were GEP-NET, 33% T-NET, 4% U-NET. Pancreas and lung were the commonest primary sites. Poorly differentiated carcinomas were <10%, all sporadic. The incidence of NET had a linear increase from 1990 to 2007 in all the centers. The mean age at diagnosis was 60.0 ± 16.4 yr, significantly anticipated in MEN1 patients (47.7 ± 16.5 yr). Association with cigarette smoking and other non-NET cancer were more prevalent than in the general Italian population. The first symptoms of the disease were related to tumor burden in 46%, endocrine syndrome in 23%, while the diagnosis was fortuity in 29%. Insulin (37%) and serotonin (35%) were the most common hormonal hypersecretions. An advanced tumor stage was found in 42%, more frequently in the gut and thymus. No differences in the overall survival was observed between T-NET and GEP-NET and between sporadic and MEN1-associated tumors at 10 yr from diagnosis, while survival probability was dramatically reduced in U-NET. CONCLUSIONS The data obtained from this study furnish relevant information on epidemiology, natural history, and clinico-pathological features of NET, not available from the few published Register studies.
Collapse
Affiliation(s)
- A Faggiano
- Department of Molecular and Clinical Endocrinology and Oncology, Section of Endocrinology, University of Naples "Federico II", Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2012; 24:152-60. [PMID: 22967994 DOI: 10.1093/annonc/mds276] [Citation(s) in RCA: 641] [Impact Index Per Article: 53.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. PATIENTS AND METHODS Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. RESULTS The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67<55% was by receiver operating characteristic analysis the best cut-off value concerning correlation to the response rate. Patients with Ki-67<55% had a lower response rate (15% versus 42%, P<0.001), but better survival than patients with Ki-67≥55% (14 versus 10 months, P<0.001). Platinum schedule did not affect the response rate or survival. The most important negative prognostic factors for survival were poor performance status (PS), primary colorectal tumors and elevated platelets or lactate dehydrogenase (LDH) levels. CONCLUSIONS Advanced GI-NEC patients should be considered for chemotherapy treatment without delay.PS, colorectal primary and elevated platelets and LDH levels were prognostic factors for survival. Patients with Ki-67<55% were less responsive to platinum-based chemotherapy, but had a longer survival. Our data indicate that it may not be correct to consider all GI-NEC as one single disease entity.
Collapse
Affiliation(s)
- H Sorbye
- Department of Oncology, Haukeland University Hospital, Bergen, Norway.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Tanaka Y, Ogawa H, Uchino K, Ohbayashi C, Maniwa Y, Nishio W, Nakao A, Yoshimura M. Immunohistochemical studies of pulmonary large cell neuroendocrine carcinoma: a possible association between staining patterns with neuroendocrine markers and tumor response to chemotherapy. J Thorac Cardiovasc Surg 2012; 145:839-46. [PMID: 22498090 DOI: 10.1016/j.jtcvs.2012.03.036] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2011] [Revised: 01/26/2012] [Accepted: 03/16/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVE Pulmonary large cell neuroendocrine carcinoma is a rare high-grade malignant tumor. Because large cell neuroendocrine carcinoma is rare, the optimal treatment, including perioperative chemotherapy, has not been defined. We retrospectively analyzed the correlation among the effectiveness of perioperative chemotherapy in treating large cell neuroendocrine carcinoma, pathologic stage, and immunoreactivity to neuroendocrine markers. METHODS A total of 63 patients with pulmonary large cell neuroendocrine carcinoma undergoing surgical resection from 2001 to 2009 were included. The resected tumors were immunohistochemically stained with the 3 neuroendocrine markers synaptophysin, chromogranin A, and neural cell adhesion molecule. We categorized patients who were positive for all 3 markers as the triple-positive group and those who were negative for 1 or 2 markers as the non-triple-positive group. RESULTS Perioperative chemotherapy resulted in better overall survival than surgery alone (P = .042). Multivariate analysis of survival revealed that perioperative chemotherapy was a significant independent prognostic factor (hazard ratio, 0.323; 95% confidence interval, 0.112-0.934; P = .0371). Among the patients who received perioperative chemotherapy, the non-triple-positive group had a significantly greater 5-year survival rate than the triple-positive group (P = .0216). Moreover, among the non-triple-positive group, a significantly greater 5-year survival rate was observed for the patients who underwent surgery with chemotherapy than for those who underwent surgery without chemotherapy (P = .0081). In contrast, no difference was found in 5-year survival between patients with chemotherapy and those without chemotherapy when the tumors were triple positive. CONCLUSIONS Our results suggest that perioperative chemotherapy might benefit the survival of patients with pulmonary large cell neuroendocrine carcinoma, in particular when the tumors are not immunoreactive to all 3 neuroendocrine markers.
Collapse
Affiliation(s)
- Yugo Tanaka
- Department of Thoracic Surgery, Hyogo Cancer Center, Akashi City, Hyogo, Japan
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Oberstein PE, Kenney B, Krishnamoorthy SK, Woo Y, Saif MW. Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature. Clin Colorectal Cancer 2012; 11:218-23. [PMID: 22421002 DOI: 10.1016/j.clcc.2012.01.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 12/16/2011] [Accepted: 01/20/2012] [Indexed: 02/08/2023]
Affiliation(s)
- Paul E Oberstein
- Columbia University, College of Physicians and Surgeons at New York-Presbyterian Hospital, New York, NY 10032, USA
| | | | | | | | | |
Collapse
|
28
|
Marotta V, Nuzzo V, Ferrara T, Zuccoli A, Masone M, Nocerino L, Del Prete M, Marciello F, Ramundo V, Lombardi G, Vitale M, Colao A, Faggiano A. Limitations of Chromogranin A in clinical practice. Biomarkers 2012; 17:186-91. [PMID: 22303881 DOI: 10.3109/1354750x.2012.654511] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
CONTEXT Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool. METHODS Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay. RESULTS The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions. CONCLUSION Serum CgA is not helpful for the first-line diagnosis of NEN.
Collapse
Affiliation(s)
- Vincenzo Marotta
- Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Large cell neuroendocrine carcinoma of the head and neck. Oral Oncol 2011; 48:211-5. [PMID: 22024350 DOI: 10.1016/j.oraloncology.2011.09.016] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2011] [Revised: 09/27/2011] [Accepted: 09/29/2011] [Indexed: 11/21/2022]
Abstract
Large cell neuroendocrine carcinoma is a poorly differentiated neuroendocrine carcinoma that usually occurs in the lung. Although rare in the head and neck, salivary and mucosal subtypes are recognized. This article describes their characteristic light microscopic and immunohistochemical features and highlights the importance of accurate diagnosis, management and prognostic implications.
Collapse
|
30
|
Zhang R, He Y, Zhang X, Xing B, Sheng Y, Lu H, Wei Z. Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. Cancer Lett 2011; 314:155-65. [PMID: 22014978 DOI: 10.1016/j.canlet.2011.09.027] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2011] [Revised: 09/19/2011] [Accepted: 09/20/2011] [Indexed: 11/27/2022]
Abstract
Uncontrolled estrogen exposure can induce an imbalance in BCL2/BAX expression in endometrial cells, leading to precancerous lesions and type I endometrial adenocarcinoma. This study aimed to explore the mechanism underlying this phenomenon. We show that the activated estrogen receptor can suppress the expression of BAX by upregulating a group of microRNAs including hsa-let-7 family members and hsa-miR-27a, thereby promoting an increased BCL2/BAX ratio as well as enhanced survival and proliferation in the affected cells. These ER-regulated hsa-let-7 microRNAs can be detected in most hyperplastic endometria, suggesting their potential utility as indicators of estrogen over-exposure.
Collapse
Affiliation(s)
- Rong Zhang
- Department of Obstetrics and Gynecology, Fengxian Central Hospital, Shanghai 201400, PR China.
| | | | | | | | | | | | | |
Collapse
|
31
|
Should Large Cell Neuroendocrine Lung Carcinoma be Classified and Treated as a Small Cell Lung Cancer or with Other Large Cell Carcinomas? J Thorac Oncol 2011; 6:1050-8. [DOI: 10.1097/jto.0b013e318217b6f8] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
32
|
Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treat Rev 2011; 37:358-65. [PMID: 21481536 DOI: 10.1016/j.ctrv.2011.03.002] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2011] [Revised: 03/01/2011] [Accepted: 03/13/2011] [Indexed: 01/30/2023]
Abstract
INTRODUCTION Neuroendocrine carcinomas of unknown primary (NCUP) represent a specific subset with relatively favorable prognosis. Data on biology, management and outcome of NCUP patients have not been systematically reviewed neither compared to those of neuroendocrine tumors of known primary. PATIENTS AND METHODS We systematically reviewed all publications studying neuroendocrine CUP patients and presented a single center retrospective patient series. In addition, we analyzed and specified the similarities and/or differences between NCUP and other neuroendocrine malignancies. RESULTS Five hundred patients with NCUP constituted a heterogeneous cohort in terms of histology, grade, anatomic site and tumor biology in published series and were managed mostly with platinum-based regimens. Among 294 patients with available outcome data, a median survival of 15.5 months (range 11.6-40) was observed. Comparative analysis with neuroendocrine solid tumors (NET) revealed that poorly-differentiated NCUP share an aggressive natural history and a dismal prognosis similar to high grade pulmonary and extrapulmonary neuroendocrine carcinomas (Large Cell Neuroendocrine bronchial Carcinomas, LCNEC and poorly differentiated gastroenteropancreatic tumors, GEP-NET). Well differentiated NCUP reveal a more indolent course with a survival range resembling that of typical and atypical pulmonary carcinoids, well differentiated gastrointestinal NETs and limited small cell lung carcinomas. CONCLUSION No evidence for distinct biology or outcome of NCUP patients emerged when histological grade was matched for known primary NETs. The high heterogeneity of the NCUP subgroup limits the potential for identification of reliable prognosticators and hinders development of novel targeted therapies.
Collapse
|
33
|
de Herder WW, Mazzaferro V, Tavecchio L, Wiedenmann B. Multidisciplinary approach for the treatment of neuroendocrine tumors. TUMORI JOURNAL 2011; 96:833-46. [PMID: 21302641 DOI: 10.1177/030089161009600537] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Wouter W de Herder
- Department of Internal Medicine, Section of Endocrinology Erasmus MC, Rotterdam, The Netherlands
| | | | | | | |
Collapse
|
34
|
Abgral R, Leboulleux S, Déandreis D, Aupérin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J, Ducreux M, Schlumberger M, Baudin E. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011; 96:665-71. [PMID: 21193541 DOI: 10.1210/jc.2010-2022] [Citation(s) in RCA: 81] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
OBJECTIVE The purpose of this prospective study was to compare the performance of (111)In-octreotide somatostatin receptor scintigraphy (SRS) and (18)fluorodesoxyglucose positron emission tomography (FDG-PET) in aggressive well-differentiated endocrine carcinoma (WDEC) defined by a high Ki67 (≥10%). METHODS Eighteen consecutive patients explored in a single hospital between November 2003 and 2008 for high Ki67 (≥10%) WDEC were prospectively included. WDEC were sporadic in 17 cases and secreting in 16 cases. FDG-PET, SRS, and computed tomography (CT) were performed within a maximum of 3 months and reviewed by two independent readers. For each patient, an analysis per organ and lesion was performed. Both the results of conventional imaging and the highest number of metastatic organs and distinct lesions visualized by all imaging methods including SRS, FDG-PET, and thoraco-abdomino-pelvic CT were considered for the determination of the standard. Correlation between tumor slope and maximum standardized uptake value, Ki67 value, and grade of uptake at SRS was evaluated. RESULTS FDG-PET, SRS, and CT showed at least one lesion in 18 (100%), 15 (83%), and 17 (94%) patients, respectively. A total of 254 lesions were diagnosed in 59 organs. FDG-PET, SRS, and CT detected 195 (77%), 109 (43%), and 195 (77%) lesions in 53 (90%), 30 (51%), and 39 (66%) organs, respectively. FDG-PET, compared to SRS, detected more, the same as, and less lesions in 14 (78%), one (6%), and three (17%) patients, respectively. A statistical trend was found between Ki67 value and tumor slope (P = 0.07). Median survival after diagnosis was 25 months (range, 6-71 months). CONCLUSION These results suggest that FDG-PET is more sensitive than the SRS for high Ki67 WDEC staging.
Collapse
Affiliation(s)
- Ronan Abgral
- Department of Nuclear Medicine, University Hospital of Brest, 29200 Brest, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Patel KJ, Chandana SR, Wiese DA, Olsen B, Conley BA. Unusual Presentation of Large-Cell Poorly Differentiated Neuroendocrine Carcinoma of the Epiglottis. J Clin Oncol 2010; 28:e461-3. [DOI: 10.1200/jco.2010.28.6237] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Large cell/neuroendocrine carcinoma. Lung Cancer 2010; 69:13-8. [DOI: 10.1016/j.lungcan.2009.12.011] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2009] [Revised: 12/04/2009] [Accepted: 12/20/2009] [Indexed: 11/21/2022]
|
37
|
Stojsic J, Stevic R, Kontic M, Stojsic Z, Drndarevic N, Bunjevacki V, Jekic B. Large cell lung carcinoma with unusual imaging feature, immunophenotype and genetic finding. Pathol Oncol Res 2010; 17:175-9. [PMID: 20405348 DOI: 10.1007/s12253-010-9272-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2009] [Accepted: 04/06/2010] [Indexed: 11/30/2022]
Abstract
We present a case of large cell lung carcinoma in sixty-one year old male with typical lung cancer symptoms but unusual radiological presentation and immunophenotype. Tumor morphological finding related to its radiological finding was suggestive for large cell lymphoma or carcinoma, but its immunophenotype made confusion for pathological diagnosis. No p53 mutations were detected in genetic investigation. Multidisciplinary diagnostic approach to some tumors is useful for their final diagnosis.
Collapse
Affiliation(s)
- Jelena Stojsic
- Institute for Lung Diseases and Tuberculosis, Clinical Centre of Serbia, Belgrade, Serbia.
| | | | | | | | | | | | | |
Collapse
|
38
|
Demoreuil C, Thirot-Bidault A, Dagher C, Bou-Farah R, Benbrahem C, Lazure T, Gayral F, Buffet C. [Poorly differentiated large cell endocrine carcinoma of the extrahepatic bile ducts]. ACTA ACUST UNITED AC 2009; 33:194-8. [PMID: 19233580 DOI: 10.1016/j.gcb.2009.01.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2008] [Revised: 12/05/2008] [Accepted: 01/03/2009] [Indexed: 12/14/2022]
Abstract
We report a case of a poorly differentiated endocrine large cell carcinoma of the extrahepatic bile ducts in a 73-year-old man, revealed by abdominal pain, jaundice and weight loss. Computed tomography and endoscopic retrograde cholangiography found tumoral stenosis of the main bile duct. Brush cytology detected tumor cells. Pathological examination of the resected bile duct disclosed a high-grade large cell carcinoma with morphological endocrine features and positivity for chromogranin A. This tumor was associated with a minor component of adenocarcinomatous cells. Despite polychemotherapy, the patient had widely metastatic disease a few months later. We discuss here the histogenesis of this tumor as well as its nosological position among the endocrine and mixed tumors of bile ducts.
Collapse
Affiliation(s)
- C Demoreuil
- Service d'hépatogastroentérologie, CHU de Bicêtre, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre cedex, France
| | | | | | | | | | | | | | | |
Collapse
|
39
|
Proceedings of the IASLC International Workshop on Advances in Pulmonary Neuroendocrine Tumors 2007. J Thorac Oncol 2009; 3:1194-201. [PMID: 18827620 DOI: 10.1097/jto.0b013e3181861d7b] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The International Association for the Study of Lung Cancer, (IASLC) International Congress on Advances in Pulmonary Neuroendocrine Tumors was a two-day meeting held at the Royal Brompton Hospital in London, United Kingdom on the thirteenth and forteenth of December 2007. The meeting was led by 14 member international faculty-in the disciplines of pathology, surgery, medicine, oncology, endocrinology, nuclear medicine, diagnostic imaging, and biostatistics. The aims were twofold, as an educational meeting, and to develop the IASLC International Pulmonary Neuroendocrine Tumors Registry. The meeting highlighted the difference in presentation of the tumors, management options for early and advanced stage disease including the use of novel agents and approaches. The need, process, and approach to an International Registry of Pulmonary Neuroendocrine Tumors were emphasized. International collaboration to develop a retrospective registry, prospective data collection, virtual tissue bank, and collaborative clinical trials were universally agreed as the best way to advance our understanding and treatment of these rare tumors.
Collapse
|